History

CagriSema pairs Novo Nordisk's investigational amylin analog cagrilintide with its already-approved GLP-1 drug semaglutide. The pivotal Phase 3 REDEFINE program reported its first topline in December 2024 at 22.7% weight loss — below the roughly 25% the company had signaled, which moved the share price. REDEFINE 1 (obesity) and REDEFINE 2 (type 2 diabetes) were published in the New England Journal of Medicine in June 2025, Novo filed a New Drug Application with the FDA on 18 December 2025, and in February 2026 the open-label REDEFINE 4 head-to-head against tirzepatide reported that it had missed its primary non-inferiority endpoint. The cardiovascular outcomes trial REDEFINE 3 remains ongoing.

CagriSema is one of the most heavily studied combination products in the obesity-drug pipeline, and also a useful case study in why “strong trial data” and “proven, approved, and better than the alternatives” are not the same thing. It is a once-weekly injectable that fixes two peptides into a single product: cagrilintide, a long-acting amylin analog, plus semaglutide 2.4 mg, the GLP-1 drug already sold as Wegovy. The combination has been run through large randomized trials published in top journals — but it is not approved anywhere, it undershot its own company’s expectations, and a head-to-head trial against tirzepatide failed to show it was even non-inferior. This is not medical advice, and this profile does not cover dosing.

What it is

CagriSema combines two appetite-regulating peptides that work through partly distinct pathways. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist: it acts along the gut-brain axis to increase satiety, slow gastric emptying, trigger glucose-dependent insulin release, and reduce glucagon. Cagrilintide is an analog of amylin, a pancreatic hormone that signals fullness; it activates amylin and calcitonin receptors in the brainstem (area postrema) and hypothalamus to reduce food intake through a mechanism that is largely separate from GLP-1.

The rationale is that engaging two complementary satiety circuits at once should produce more weight loss than either agent alone. The pivotal Phase 3 trial was built to test exactly that, with separate arms for the combination, semaglutide alone, cagrilintide alone, and placebo.

The claims

In legitimate development, CagriSema is being studied for chronic weight management in adults with obesity, or overweight plus at least one weight-related comorbidity, and for combined weight loss and blood-sugar control in people with type 2 diabetes. Novo Nordisk has said that, if approved, it would be the first once-weekly injectable combining a GLP-1 receptor agonist and an amylin analog for weight management.

The headline promise circulating around CagriSema was that two satiety mechanisms stacked together would deliver weight loss beyond what GLP-1 drugs alone achieve — and beyond tirzepatide. The trial data complicate both halves of that claim.

What the evidence actually shows

The human dataset is large and, for the two published trials, high quality.

Obesity without diabetes (REDEFINE 1; NCT05567796): A Phase 3 trial of 3,417 adults randomized to CagriSema, semaglutide alone, cagrilintide alone, or placebo over 68 weeks. CagriSema produced about 22.7% mean weight loss (trial-product estimand); on the treatment-policy estimand it was −20.4% versus −3.0% on placebo. More than half of CagriSema patients reached at least 20% weight loss, and over 90% reached at least 5%. Two honest caveats: the 22.7% result fell short of the roughly 25% management had signaled at the December 2024 topline, and it was framed as a disappointment. Published by Garvey and colleagues in NEJM (PMID 40544433).
Type 2 diabetes (REDEFINE 2; NCT05394519): A Phase 3 trial of 1,206 adults. CagriSema produced about 13.7% weight loss versus 3.4% on placebo (treatment-policy estimand; estimated treatment difference about 10.4 percentage points), and 73.5% of CagriSema patients reached an HbA1c of 6.5% or lower versus 15.9% on placebo, with an HbA1c reduction in the range of roughly 1.8 to 1.9 percentage points. Published by Davies and colleagues in NEJM (PMID 40544432).
Head-to-head against tirzepatide (REDEFINE 4): An open-label Phase 3 trial of 809 adults over 84 weeks reported in February 2026 as a company top-line result. CagriSema produced 23.0% weight loss versus 25.5% for tirzepatide 15 mg (efficacy estimand; 20.2% versus 23.6% on the treatment-regimen estimand). Critically, the trial did NOT meet its primary endpoint of non-inferiority to tirzepatide. This is company top-line data; a peer-reviewed publication is not yet confirmed.
Cardiovascular outcomes (REDEFINE 3): An ongoing, event-driven Phase 3 trial of roughly 7,000 adults with established cardiovascular disease (with or without type 2 diabetes). There are no cardiovascular outcome results yet.
Body composition (REDEFINE 1 DXA subset, n = 252): In this prespecified subgroup, about two-thirds of the weight lost was fat mass (66.9%) and about one-third was lean soft tissue (33.1%) — a relatively favorable ratio, but lean-mass loss accompanies large total weight loss. Reported at ObesityWeek 2025.

The strongest evidence — REDEFINE 1 and REDEFINE 2 — is large, randomized, and peer-reviewed. The tirzepatide comparison and body-composition figures are company top-line and congress-presentation data, not yet peer-reviewed papers, and long-term cardiovascular benefit remains an open question until REDEFINE 3 reports.

Legal and regulatory status

CagriSema is not approved by the FDA or any other regulator as of mid-2026; it is investigational. Novo Nordisk submitted a New Drug Application to the FDA on 18 December 2025 for chronic weight management, with review expected during 2026.

For athletes, the situation is frequently misreported. GLP-1 receptor agonists, including semaglutide, are not prohibited in sport for 2026 — they sit on WADA’s Monitoring Program (semaglutide since 2024; for 2026 the program was adjusted to also monitor markers of tirzepatide). Monitoring-Program status carries no anti-doping rule violation and requires no Therapeutic Use Exemption. The claim circulating online that GLP-1s were moved to a prohibited class (S4, “Hormone and Metabolic Modulators”) in January 2026 is false, per USADA’s GLP-1 advisory and WADA’s 2026 publications. WADA is evaluating a possible future ban, but none is in effect. (For context, growth factors such as IGF-1 and MGF are separately prohibited under S2 — a different class from incretin and amylin peptides.)

Safety

The dominant adverse effects are gastrointestinal. In REDEFINE 1, GI adverse events occurred in 79.6% of CagriSema patients versus 39.9% on placebo, including nausea, constipation, and vomiting; most were mild-to-moderate, related to dose titration, and diminished over time across REDEFINE 1 and 4. Discontinuation due to adverse events was in the low single digits, modestly above placebo.

A REDEFINE 1 analysis in Hypertension (PMID 41328546) found greater blood-pressure reduction with CagriSema than placebo (systolic −10.9 versus −2.8 mm Hg; diastolic −5.4 versus −1.7 mm Hg) — but this is a risk-factor analysis, not a cardiovascular-outcomes result; those await REDEFINE 3. As with any large weight loss, some lean-mass loss accompanies the fat loss, though the fat-to-lean ratio in the DXA subset was relatively favorable.

Several warnings are class-level extrapolations from the GLP-1 class rather than CagriSema-specific trial findings: a thyroid C-cell tumor warning based on rodent studies (contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2), pancreatitis, gallbladder events, and an emerging, under-investigation pharmacovigilance signal for non-arteritic anterior ischemic optic neuropathy (NAION). Treat these as class-level and, in the NAION case, still under investigation.

Bottom line

CagriSema has genuinely strong randomized human evidence for weight loss in two large, peer-reviewed Phase 3 trials — in obesity and in type 2 diabetes — which is more than almost any compound discussed on peptide forums can claim. But the story is more cautious than the early hype suggested: it undershot its own company’s headline expectations, it failed to prove non-inferiority against tirzepatide in a direct head-to-head, it is not approved anywhere, and the cardiovascular outcomes trial has not reported. The efficacy is well established by high-quality trials; everything about its place relative to existing drugs, its long-term outcomes, and its regulatory future is still unsettled.

Evidence grade: Strong human.